Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA ...

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet ...

Sruthi Arepalli, MD, an assistant professor at Emory Eye Center in Atlanta, Georgia, presented a comprehensive study on secondary lens implants in patients with uveitis at the 2025 ASRS meeting.

Lai spoke with Modern Retina about the study of PER-001, a novel therapeutic targeting the endothelin-1 receptor. Michael Lai, MD, PhD, presented at the 2025 annual scientific meeting of the American ...

At the 2025 annual scientific meeting of the American Society of Retina Specialists (ASRS), Jay Chhablani, MD, Vice Chair at University of Pittsburgh Medical Center gave a presentation titled, "Safety ...

Panelists discuss how their management approach for geographic atrophy (GA) has evolved from a “come back in a year” mentality to actively offering treatment discussions within 2 to 3 months, with ...

EP: 4. Choosing Between the Currently Available GA Therapies Therapy selection between the 2 FDA-approved geographic atrophy treatments presents a complex clinical decision without clear superiority ...

Retina Group of WashingtonLai spoke with Modern Retina about the study of PER-001, a novel therapeutic targeting the endothelin-1 receptor.

Nimesh A. Patel, MD, FASRS, from Mass Eye and Ear Hospital and Boston Children's Hospital presented a real-world study using the Vestrum database to examine usage trends for pegcetacoplan and ...

Newsletter Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.